Bausch + Lomb (NYSE:BLCO) PT Raised to $22.00 at HC Wainwright

Bausch + Lomb (NYSE:BLCO) had its price target raised by HC Wainwright from $19.00 to $22.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank of Canada reiterated an outperform rating and issued a $20.00 target price on shares of Bausch + Lomb in a research note on Thursday, August 1st. Evercore lifted their price objective on shares of Bausch + Lomb from $15.50 to $17.00 and gave the company an in-line rating in a research report on Thursday, August 1st. Needham & Company LLC restated a hold rating on shares of Bausch + Lomb in a research report on Monday, September 16th. Stifel Nicolaus lifted their price target on Bausch + Lomb from $16.00 to $19.00 and gave the company a hold rating in a report on Monday. Finally, Evercore ISI increased their price objective on Bausch + Lomb from $15.00 to $15.50 and gave the stock an in-line rating in a report on Tuesday, July 2nd. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $19.14.

Bausch + Lomb Trading Up 0.1 %

NYSE BLCO opened at $19.04 on Monday. The firm has a market capitalization of $6.70 billion, a PE ratio of -19.83, a price-to-earnings-growth ratio of 1.81 and a beta of 0.46. Bausch + Lomb has a one year low of $13.16 and a one year high of $21.00. The company has a 50-day simple moving average of $16.67 and a 200-day simple moving average of $15.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.01 and a current ratio of 1.65.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, July 31st. The company reported $0.13 EPS for the quarter, meeting analysts’ consensus estimates of $0.13. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.17 billion. Bausch + Lomb had a positive return on equity of 3.36% and a negative net margin of 10.15%. Bausch + Lomb’s quarterly revenue was up 17.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 earnings per share. On average, equities analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current year.

Insider Buying and Selling at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders acquired 32,250 shares of the stock in a transaction dated Monday, August 5th. The shares were bought at an average price of $15.66 per share, with a total value of $505,035.00. Following the purchase, the chief executive officer now directly owns 595,169 shares of the company’s stock, valued at approximately $9,320,346.54. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BLCO. Blue Trust Inc. lifted its position in shares of Bausch + Lomb by 14,052.2% during the 2nd quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock valued at $47,000 after acquiring an additional 3,232 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Bausch + Lomb during the second quarter valued at $173,000. Fore Capital LLC acquired a new position in shares of Bausch + Lomb in the 1st quarter valued at $384,000. Renaissance Capital LLC increased its stake in Bausch + Lomb by 3.0% in the 1st quarter. Renaissance Capital LLC now owns 23,076 shares of the company’s stock worth $399,000 after purchasing an additional 669 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Bausch + Lomb during the 2nd quarter worth about $580,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.